ACP-5862 is a major active and pyrrolidine ring-opened metabolite of Acalabrutinib (IC50: 5.0 nM for BTK). Acalabrutinib is an irreversible and highly selective...
IBT6A is an impurity of Ibrutinib. Ibrutinib is a Btk inhibitor (IC50: 0.5 nM). IBT6A can be used in the synthesis of IBT6A Ibrutinib dimer and IBT6A adduct. |
||Btk inhibitor 2
Btk inhibitor 2 is a BTK inhibitor extracted from patent US 20170224688 A1 (BGB-3111 analog). |
GDC-0834 inhibits BTK with an in vitro IC50 of 5.9 and 6.4 nM in biochemical and cellular assays, respectively, and in vivo IC50 of 1.1 and 5.6 μM in mouse and...
||N-piperidine Ibrutinib hydrochloride
N-piperidine Ibrutinib hydrochloride is an potent inhibitor of BTK (WT BTK and C481S BTK with IC50s of 51.0 and 30.7 nM, respectively). |
Tirabrutinib hydrochloride is a selective and novelBTK with IC50 2.2 nm inhibitor. |
Orelabrutinib is an orally active and irreversible inhibitor of Bruton's tyrosine kinase (BTK). |
PRN1008 is a reversible covalent, selective and oral active inhibitor of Bruton’s Tyrosine Kinase (BTK)(IC50 of 1.3 nM). |
PF-06250112 is an effective and highly selective BTK inhibitor (IC50: 0.5 nM. PF-06250112 displays an inhibitory effect toward BMX nonreceptor tyrosine kinase a...
ARQ-531 is a potent and orally active BTK inhibitor with potential antineoplastic activity, with IC50s of 0.85 nM and 0.39 nM for WT-BTK and C481S-BTK, respecti...
Spebrutinib besylate (AVL-292 benzenesulfonate; CC-292 besylate) is a Btk kinase activity inhibitor (IC50<0.5 nM, Kinact/Ki=7.69×104 M-1s-1s). |
BMS-935177 is a potent and selective reversible inhibitor of Bruton’s tyrosine kinase (Btk), with an IC50 of 3 nM. |
BMX-IN-1 is a selective and irreversible bone marrow tyrosine kinase on chromosome X (BMX)inhibitor that targets Cys496 in the BMX ATP binding domain with an IC...
CHMFL-BTK-01 is an irreversible inhibitor of BTK (IC50: 7 nM) and also potently inhibits BTK Y223 auto-phosphorylation. |
G-744 is a selective and orally active inhibitor of Btk (IC50: 2 nM). G-744 is well-tolerated, metabolically stable. It also has an efficacious to treat arthrit...
Naluzotan is an effective and selective amidosulfonamide 5-HT1A agonist with IC50 and Ki of appr 20 nM and 5.1 nM. Naluzotan is used for the treatment of anxiet...
PCI-33380 is an irreversible inhibitor of Bruton's Tyrosine Kinase. |
Remibrutinib inhibits BTK activity with an IC50 value of 0.023 μM in blood. Remibrutinib is an effective and orally active Bruton tyrosine kinase inhibitor (IC...
SB-633825 can inhibit cancer cell growth and angiogenesis. SB-633825 is an effective and ATP-competitive inhibitor of TIE2, LOK, and BRK (IC50s: 3.5 nM, 66 nM, ...
Tilfrinib is an effective and selective inhibitor of breast tumor kinase (IC50: 3.15 nM), which displays anti-proliferative activity. |
Ibrutinib is an irreversible inhibitor of BTK (IC50: 0.5 nM) that selectively blocks B cell activation. |
RN486 is an effective and specific BTK inhibitor (IC50: 4 nM). |
CNX-774 is a highly specific, irreversible, and orally active BTK inhibitor (IC50<1 nM). |
CGI1746 is a potent and highly selective small-molecule Btk inhibitor with IC50 of 1.9 nM. |
PLX-4720 is a potent and selective inhibitor of B-Raf (V600E) (IC50: 13 nM), equally potent to c-Raf-1(Y340D and Y341D mutations). |
Spebrutinib is an orally bioavailable, selective inhibitor of Bruton's agammaglobulinemia tyrosine kinase (BTK), with potential antineoplastic activity. |
Avitinib, also known as AC0010 or AC0010MA, is an orally available, irreversible, epidermal growth factor receptor (EGFR) mutant-selective inhibitor, with poten...
Acalabrutinib, also known as ACP-196, is an orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administra...
CHMFL-BMX-078 is a highly potent and selective type II irreversible BMX kinase inhibitor with an IC50 of 11 nM. |
PCI 29732 is a selective and irreversible Btk inhibitor with IC50 of 8.2 nM in a FRET based biochemical enzymology assay. |
||Syk Inhibitor II (hydrochloride)
Spleen tyrosine kinase (Syk) is a non-receptor tyrosine kinase that, upon phosphorylation, binds to immunoreceptor tyrosine-based activation motifs of FcRγ cha...
BMS-986142 is a potent and highly selective reversible BTK inhibitor (IC50: 0.5 nM). |
BMS986195 is a potent, covalent inhibitor of Bruton's tyrosine kinase (BTK), >5,000-fold selective over all kinases outside of the Tec family (IC50 <1 nM for BT...
Saracatinib (AZD0530) is an effective Src inhibitor (IC50: 2.7 nM), and effective to Lck, Fyn, Lyn, Blk, Fgr and c-Yes. |
LFM-A13（IC50=2.5 μM）, a specific Bruton's tyrosine kinase (BTK), is more than 100-fold specificity than other protein kinases, such as JAK1, JAK2, HCK, EGF...
Olmutinib is an orally available small molecule, a mutant-selective inhibitor of epidermal growth factor receptor (EGFR) with potential antineoplastic activity....
ONO-4059 analogue is an analogue of ONO-4059, which is a highly potent and selective oral BTK inhibitor with IC50 of 23.9 nM. Phase 1. |
Zanubrutinib is an inhibitor of Bruton tyrosine kinase (BTK). |
Ibrutinib deacryloylpiperidine is a highly selective Bruton’s tyrosine kinase (BTK) irreversible inhibitor with an IC50 of 0.5 nM. |
(±)-Zanubrutinib is a specific, potent and orally available Btk inhibitor. |
BTK IN-1 (SNS062 analog) is an effective BTK inhibitor (IC50: <100 nM). |
Tirabrutinib (ONO-4059) is a highly specific and orally bioavailable BTK inhibitor (IC50: 2.2 nM). |
Fenebrutinib (GDC-0853) is a selective and noncovalent Btk inhibitor (Ki: 0.91 nM). |